Tier II mutagenic screening of 13 NIOSH priority compounds, individual compound report, butylene oxide, report no. 28.
Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, Contract 210-78-0026, 1981 Feb; :1-187
The Tier II mutagenic screening of butylene-oxide (109999) (BO) was conducted. The unschedule DNA synthesis (UDS) assay was conducted with human embryonic intestinal cells, rat liver S9, and 11 to 7300 micrograms per milliliter BO. A cytogenetic analysis of rat bone marrow cells was performed after in-vivo exposure to 250 or 1000 parts per million (ppm) BO for 7 hours per day for 1 or 5 days. Dominant lethal test in male rats and sperm abnormality tests in male mice were performed after in-vivo exposure to 250 or 1000ppm BO for 7 hours per day for 5 days. The sex linked recessive lethal test was performed using Drosophila-melanogaster after a 7 hour exposure to 1000ppm. BO produced no increases in UDS, sperm abnormality frequency, or sex linked recessive lethal mutation frequency. No effects due to BO exposure were observed in the dominant lethal assay. The author concludes that BO showed no mutagenic activity under these test conditions.
NIOSH-Contract; Contract-210-78-0026; Screening-methods; Bioassays; Mutagenesis
Final Contract Report
NTIS Accession No.
National Institute for Occupational Safety and Health
Inveresk Research International Limited, Musselburgh, Scotland